会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明公开
    • 엘라그산을 포함하는 동맥경화증, 고지혈증 및 지방간의예방 및 치료용 조성물
    • 含有鞣制,酸性或非酸性的组合物,用于预防和治疗肠梗塞,高血压和肝脏疾病
    • KR1020010015510A
    • 2001-02-26
    • KR1020000062334
    • 2000-10-23
    • 한국과학기술연구원
    • 복성해정태숙배기환박용복최명숙문석식권용국이은숙현병화최양규이철호안병태이새봄
    • A61K31/366
    • PURPOSE: A composition containing tannin, gallic acid or ellagic acid is provided for preventing and treating arteriosclerosis, hyperlipemia and liver diseases. CONSTITUTION: When tannin, gallic acid or ellagic acid are administrated into an animal body, they prevent the deposition of macrophage-lipid complex within the inner surface of arterial duct, decrease the concentration of GOT(glutamate-oxaloacetate transaminase), GPT(glutamate-pyruvate transaminase), gammaGTP(gamma-glutamyl transpeptidase), and lipid in serum, and strongly inhibit the damage of liver cells and the progress of fatty liver. The composition contains an effective of ellagic acid displaying an anticancer activity, that is 0.1 mg to 500 mg/weight kg a day. The composition is preferably administrated into an animal body 5 times a day in a dosage of 1 mg to 100 mg/weight kg.
    • 目的:提供含有单宁,没食子酸或鞣花酸的组合物,用于预防和治疗动脉硬化,高脂血症和肝脏疾病。 构成:当将单宁,没食子酸或鞣花酸施用于动物体内时,可防止巨噬细胞 - 脂质复合物在动脉管内表面沉积,降低GOT(谷氨酸 - 草酰乙酸转氨酶)浓度,GPT(谷氨酸 - 丙酮酸转氨酶),γGTP(γ-谷氨酰转肽酶)和血清中的脂质,并且强烈地抑制肝细胞的损伤和脂肪肝的进展。 组合物含有显示抗癌活性的有效的鞣花酸,即每天0.1mg至500mg /重量kg。 组合物优选以1mg至100mg / kg kg的剂量每天施用5次。
    • 7. 发明公开
    • 네오헤스페리딘디하이드로칼콘을포함하는동맥경화증,고지혈증,간질환,고혈당증의예방및치료용조성물
    • 包含NEOHESPERIDIN DIHYDROCHALCONE的组合物,用于预防和治疗高脂血症,肠梗塞,肝病和高血压
    • KR1020000019720A
    • 2000-04-15
    • KR1019980037963
    • 1998-09-15
    • 한국과학기술연구원
    • 복성해정태숙배기환박용복최명숙문석식권용국이은숙현병화최양규이철호안병태이새봄
    • A61K31/70A23L2/04
    • A23G9/34A21D2/181A23C9/152A23L2/52A23L27/36A23L33/105
    • PURPOSE: A pharmaceutical composition and functional food and drink comprising neohesperid in dihydrochalcone are provided, for treating and preventing hyper lipidemia, arteriosclerosis, a liver disease and hyperglycemia. CONSTITUTION: The pharmaceutical composition comprises neohesperid in dihydrochalcone ineffective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of neohesperid in dihydrochalcone. Neohesperidin dihydrochalcone reduces the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase) and a lipid in blood, inhibits HMG CoA (3-hydroxy-3-methylglutaryl coenzyme) being a reduction enzyme which relates to the biosynthesis of cholesterol and ACAT (acyl CoA; cholesterol-O-acyltransferase) which transforms cholesterol into cholesteryl ester, and inhibits the damage of a liver cell and the formation of a fatty liver. Also neohesperid in dihydrochalcone strongly inhibits the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface, and reduces the concentration of blood sugar.
    • 目的:提供一种包含二氢查耳酮中新月皮的药物组合物和功能性食品和饮料,用于治疗和预防高脂血症,动脉硬化,肝脏疾病和高血糖症。 组成:药物组合物含二氢查耳酮中的新皮肤无效量; 和药学上可接受的载体。 功能性食品或饮料包含二氢查耳酮中的新鲜皮肤的0.01-20重量%,优选0.1-5重量%。 新橙皮苷二氢查耳酮降低血清GOT(谷氨酸 - 草酰乙酸转氨酶),GPT(谷氨酸 - 丙酮酸转氨酶)和血液中的脂质的浓度,抑制与生物合成相关的还原酶的HMG CoA(3-羟基-3-甲基戊二酰辅酶) 的胆固醇和ACAT(酰基CoA;胆固醇-O-酰基转移酶),其将胆固醇转化为胆固醇酯,并且抑制肝细胞的损伤和脂肪肝的形成。 二氢查耳酮中的新生皮肤也强烈地抑制巨噬细胞 - 脂质复合物沉积或吸附到试验表面,并降低血糖浓度。